Clinical trial
Stem Cell Transplant for Hemoglobinopathy
NCT00176852 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00176852 |
|---|---|
| Title | Stem Cell Transplant for Hemoglobinopathy |
| Official title | Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Collaborators | National Marrow Donor Program |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | Busulfan, Fludarabine, ATG, TLI, Cyclophosphamide, GCSF, Campath, Total Body Irradiation, Stem cell infusion |
| Enrollment | 22 |
| Start date | Jun 1, 2002 |
| Primary completion | Mar 1, 2014 |
| Completion | Jan 1, 2020 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 27, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: